• Phare
  • Validé par KD/KO

Anticorps Polyclonal de lapin anti-OTUB1

OTUB1 Polyclonal Antibody for WB, IF/ICC, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IF/ICC, Indirect ELISA

Conjugaison

Non conjugué

N° de cat : 10573-1-PBS

Synonymes

EC:3.4.19.12, hOTU1, HSPC263, OTB1, OTU domain-containing ubiquitin aldehyde-binding protein 1



Informations sur le produit

10573-1-PBS cible OTUB1 dans les applications de WB, IF/ICC, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène OTUB1 Protéine recombinante Ag0845
Nom complet OTU domain, ubiquitin aldehyde binding 1
Masse moléculaire calculée 31 kDa and 35 kDa
Poids moléculaire observé31-35 kDa
Numéro d’acquisition GenBankBC007519
Symbole du gène OTUB1
Identification du gène (NCBI) 55611
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

OTUB1 belongs to the ovarian tumor domain protease (OTU) subfamily of deubiquitinases, which could block ubiquitination leading to protein stability. OTUB1 mainly prefers k-48 and k-63 ubiquitin chains type, especially in k-48 ubiquitin chain. OTUB1 performs its deubiquitinating function via two distinct manners: the canonical and non-canonical manner. OTUB1 is involved in many critical immune response processes, containing CD8 T cell activation, PD-L1 related immune evasion, and several infectious diseases. OTUB1 plays an important role in the occurrence, proliferation, invasion, and progression of various cancers, such as bladder cancer, breast cancer, prostate cancer, and colorectal cancer (PMID: 34875341, 35296795). OTUB1 has 2 isoforms with molecular weights of 31 and 35 kDa, respectively. With phospho or ubiquitin modification or reaction, the MW of OTUB1 will be increased.

{{ptg:RelatedPrimaryAntibodies}}